{'fraction_non_alphanumeric': 0.03360488798370672, 'fraction_numerical': 0.002036659877800407, 'mean_word_length': 6.071942446043166, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prognostic and clinicopathological significance of pretreatment systemic immune-inflammation index in esophageal cancer: A systematic review and meta-analysis

Review question / Objective: We performed this systematic review and meta-analysis to investigate the prognostic value of pretreatment systemic immune-inflammation index (SII) in esophageal cancer patients and the association between SII and the clinicopathological features of esophageal cancer. Eligibility criteria: (I) involved patients diagnosed with EC histopathologically; (II) hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for pretreatment SII and survival outcomes were reported, or the correlation between SII and clinicopathological characteristics of EC was stated; (III) SII was calculated by the following formula: platelet count × neutrophil count/lymphocyte count; and (IV) a definite cut-off value of pretreatment SII was available to divide the patients into high or low SII group.